Wilms' tumor protein 1 peptide-MHC complex (WT1-pMHC)

Wilms' tumor protein 1 (WT1) is a zinc-finger transcription factor essential for the development of the urogenital system, but it is highly overexpressed in a wide range of hematological and solid malignancies (Source: UniProt P19544). The target "Wilms' tumor protein 1 peptide-MHC complex" refers to the presentation of intracellularly processed WT1 fragments on the cell surface by Major Histocompatibility Complex (MHC) molecules, most commonly HLA-A*02:01. This presentation is a critical step for immune surveillance, as it allows CD8+ cytotoxic T lymphocytes to recognize and destroy tumor cells (Source: PubMed 19509272). Because WT1 is ranked as a top priority cancer antigen by the National Cancer Institute, it has become a major focus for immunotherapy. Current therapeutic approaches include peptide vaccines like Galinpepimut-S, which stimulate the patient's own immune system, and adoptive cell therapies using T-cell receptors (TCR-T) engineered to recognize the specific WT1-pMHC complex. Additionally, TCR-like antibodies are being developed to target this complex with the specificity of a T-cell receptor but the pharmacological properties of a monoclonal antibody (Source: PubMed 23486626).

Other names

WT1-HLA complexWilms' tumor protein 1 antigenWT1 peptide-HLA-A*02:01WT1-derived peptide-MHC

Therapeutic agents target the WT1-pMHC complex to trigger a T-cell mediated immune response against cells expressing the WT1 protein. This is achieved through peptide vaccination to prime endogenous T cells, or through the administration of engineered TCR-T cells and TCR-like antibodies that specifically bind the peptide-MHC interface (Source: PubMed 23486626, 30104244).